Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L.J. Bu
Correlation of ERCC1 Expression in Peripheral Blood Lymphocytes With Outcomes of Patients With Gastric Cancer Treated With Oxaliplatin-Based Adjuvant Chemotherapy
Genetics and Molecular Research
Medicine
Genetics
Molecular Biology
Related publications
P53 Expression Status Is Associated With Cancer-Specific Survival in Stage III and High-Risk Stage II Colorectal Cancer Patients Treated With Oxaliplatin-Based Adjuvant Chemotherapy
British Journal of Cancer
Cancer Research
Oncology
Association of Thymidylate Synthase Expression and Clinical Outcomes of Gastric Cancer Patients Treated With Fluoropyrimidine-Based Chemotherapy: A Meta-Analysis
OncoTargets and Therapy
Oncology
Pharmacology
Outcomes of Advanced Gastric Cancer in Young Adult Patients Treated With First-Line Combination Chemotherapy
International Journal of Cancer Therapy and Oncology
GOLPH3 Predicts Survival of Colorectal Cancer Patients Treated With 5-Fluorouracil-Based Adjuvant Chemotherapy
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
ERCC1 mRNA Expression Is Associated With the Clinical Outcome of Non-Small Cell Lung Cancer Treated With Platinum-Based Chemotherapy
Genetics and Molecular Research
Medicine
Genetics
Molecular Biology
ERCC1 Codon 118 Polymorphism Is a Useful Prognostic Marker in Patients With Pancreatic Cancer Treated With Platinum-Based Chemotherapy
International Journal of Oncology
Cancer Research
Oncology
Adjuvant Chemotherapy With Gemcitabine and Long-Term Outcomes Among Patients With Resected Pancreatic Cancer
JAMA - Journal of the American Medical Association
Medicine
A Phase II Trial of Ixabepilone in Asian Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine-Based Chemotherapy
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Excision Repair Cross-Complementing Group-1 (ERCC1) Induction Kinetics and Polymorphism Are Markers of Inferior Outcome in Patients With Colorectal Cancer Treated With Oxaliplatin
Oncotarget
Oncology
